26S proteasome · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-1426S proteasome shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q99460. Start with cancer, then reuse UniProt Q99460 as the stable protein anchor across project notes and exports.
Start with cancer, then reuse UniProt Q99460 as the stable protein anchor across project notes and exports.
26S proteasome shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include BORTEZOMIB D-MANNITOL, CARFILZOMIB, IXAZOMIB, IXAZOMIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy26S proteasome non-ATPase regulatory subunit 1
Review this target as 26S proteasome, mapped to UniProt Q99460. ChEMBL maps the protein component as 26S proteasome non-ATPase regulatory subunit 1. Sequence length is 953 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 26S proteasome as ChEMBL target CHEMBL2364701, mapped to UniProt Q99460. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 26S proteasome is the right protein anchor across sources, using UniProt Q99460 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 26S proteasome |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | Q99460 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 26S proteasome non-ATPase regulatory subunit 1 |
| UniProt Accession | Q99460 |
| Component Type | Protein |
| Sequence Length | 953 aa |
26S proteasome non-ATPase regulatory subunit 1
Review this target as 26S proteasome, mapped to UniProt Q99460. ChEMBL maps the protein component as 26S proteasome non-ATPase regulatory subunit 1. Sequence length is 953 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
26S proteasome shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include BORTEZOMIB D-MANNITOL, CARFILZOMIB, IXAZOMIB, IXAZOMIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL325041 | 8.62 | IC50 | 2.4 | Clinical |
| CHEMBL3237863 | 8.57 | IC50 | 2.7 | Preclinical |
| CHEMBL3237862 | 8.41 | IC50 | 3.9 | Preclinical |
| CHEMBL3237864 | 8.39 | IC50 | 4.1 | Preclinical |
| CHEMBL3237867 | 8.39 | IC50 | 4.1 | Preclinical |
| CHEMBL3237873 | 8.32 | IC50 | 4.8 | Preclinical |
| CHEMBL3237865 | 8.29 | IC50 | 5.1 | Preclinical |
| CHEMBL3237860 | 8.24 | IC50 | 5.7 | Preclinical |
| CHEMBL3237866 | 8.24 | IC50 | 5.7 | Preclinical |
| CHEMBL3237868 | 8.23 | IC50 | 5.9 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 16 | 33 | 7.0 |
| cell-based format | 8 | 2 | 5.1 |